spacer
home > ebr > summer 2019 > leveraging novel therapeutics and diagnostic assays
PUBLICATIONS
European Biopharmaceutical Review

Leveraging Novel Therapeutics and Diagnostic Assays

Immunotherapy is far from a novel concept, and its history is intriguing. It all began in 1891 when Dr William B Coley attempted to creatively harness the patientís immune system. William achieved durable complete remission in several types of malignancies to include sarcoma, lymphoma, and testicular carcinoma by injecting mixtures of live and attenuated bacteria into patientsí tumours. Needless to say, we have come a long way.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Marisa Pearce is Scientific Affairs Liaison at Molecular MD, an ICON company, and has over 10 years of experience in oncology biomarker test development. She has been involved in the planning and design of molecular tests across the continuum from translational research to clinical deployment. These efforts include research use only assays for solid tumour profiling to the commercialisation of companion diagnostics for minimal residual disease monitoring. Marisa's diverse background enables her to serve as subject matter expert on the selection and use of a variety of technologies for biomarker assay development. At MolecularMD, an ICON plc company, biopharma clients have access to a fit-for-purpose, platform-agnostic approach leveraging technology platforms such as NGS, droplet digital PCR, and multiplexed IHC for the codevelopment of clinical trial assays and/or downstream diagnostics aligned with the therapeutic program objectives.
spacer
Marisa Pearce
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Kindeva Drug Delivery, Formerly 3M Drug Delivery Systems, Launches as an Independent Company

Kindeva is a leading global contract development and manufacturing organization (CDMO) that specializes in solving complex drug delivery challenges for its pharmaceutical and biotechnology customers. With approximately 900 employees, Kindeva serves customers with a wealth of expertise in formulation, product development and manufacturing. Kindeva-developed and manufactured therapies treat patients battling a host of debilitating and chronic diseases, including respiratory illnesses and cardiovascular conditions. The company's microneedle-based drug delivery platforms are currently being utilized in dozens of development programs, including programs for osteoporosis, immunotherapies, COVID-19 vaccines, and other difficult-to-deliver therapies.
More info >>

White Papers

Successfully managing the unique demands of cell therapy supply chains

PCI Pharma Services

Cell therapy professionals joined a specialist webinar by industry experts from PCI Clinical Services and TrakCel, addressing the unique complexity of an autologous therapy supply chain. Hosted by European Pharmaceutical Manufacturer magazine, the webinar was delivered by Rachel Griffiths, Associate Director, Technical Services, PCI Clinincal Services, and Dr. Matthew Lakelin, Vice President, Scientific Affairs and Business Development, TrakCel . Here, we present the white paper from that webinar event.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement